title: Work absences and expenditures for employees with autoimmune inflammatory diseases.
abstract: OBJECTIVE
  Economic burden was compared for employees with autoimmune inflammatory diseases (AutoIDs) who received anti-tumor necrosis factor (TNF) α agents, those who did not, and those with no AutoID.
  
  
  METHODS
  Retrospective claims data analysis (2000-2006). Propensity analysis created two groups: (1) adult AutoID patients with anti-TNFα therapy (AutoID/anti-TNFα) matched to those with no anti-TNFα therapy (AutoID/non-anti-TNFα), and (2) non-AutoID patients (control) matched to all AutoID patients (AutoID). Indirect, direct, and total expenditures after controlling for various covariates were compared using regression analysis.
  
  
  RESULTS
  Total direct and total expenditures were, respectively, $13,187 and $13,373 higher for AutoID/anti-TNFα group (n = 689) versus AutoID/non-anti-TNFα group (n = 2699). Indirect expenditures were not statistically different between the groups. AutoID- (n = 12,612) and control-group (n = 48,895) differences showed similar trends.
  
  
  CONCLUSIONS
  These results provide useful information to employers about the cost burden associated with AutoIDs.
authors.affiliation: School of Pharmacy, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. Kavita.Nair@ucdenver.edu
authors.forename: Kavita V
authors.initials: KV
authors.lastname: Nair
authors.forename: Ahmad B
authors.initials: AB
authors.lastname: Naim
authors.forename: Ksenia
authors.initials: K
authors.lastname: Draaghtel
authors.forename: Jill
authors.initials: J
authors.lastname: Van Den Bos
mesh_terms: D000041:Absenteeism; D000293:Adolescent; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000191:economics*; D002908:Chronic Disease; D005260:Female; D017048:Health Care Costs; D006801:Humans; D000069285:Infliximab; D007345:Insurance Claim Review / Q000191:economics; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D055815:Young Adult
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab